Media
Home
Media
- Press
Minoryx‘s Marketing Authorization Application for its lead candidate leriglitazone validated by EMA for orphan indication X-linked Adrenoleukodystrophy (X-ALD)Mataró, Barcelona, Spain, September 14, 2022 - Minoryx Therapeutics, a late-stage biotech ...14/09/2022
Minoryx raises €51 million to support Marketing Authorization Application and launch preparations for X-linked Adrenoleukodystrophy (X-ALD) therapyFunds will support the marketing authorization review process for male ...31/05/2022
Additional data from Minoryx’s Phase 2/3 ADVANCE clinical trial presented at American Neurological Association (ANA) 2021Presentation highlights reduction in cerebral lesion progression and the risk ...03/11/2021Read more
- Events
Events in 2022
Events in 2021Events in 2020Events in 201911 Nov 2019 - 13 Nov 2019BIO-Europe 2019HAMBURG11 Nov 2019 - 13 Nov 2019World Orphan Drug CongressBARCELONA
